For the last few years the FDA has been engaging with drug developers to reform how dose optimisation is approached for new cancer drugs. In August 2024 they finalised the eagerly-awaited guidance for industry. As part of our collaboration, Weatherden and Physiomics have worked together to help you understand and put this framework into action.

Despite significant advances in biology, chemistry, and drug development platforms, drug attrition rates have remained stagnant in recent years. Dr Duncan McHale, co-founder of Weatherden, explores some of the ways big pharma has tried to tackle this problem – and why they’ve largely fallen short.